Comparison of different serum prostate specific antigen measures for early prostate cancer detection
โ Scribed by William J. Catalona; Deborah S. Smith
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 335 KB
- Volume
- 74
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)
## Background: It is not yet known whether screening for the detection of early prostate carcinoma will reduce mortality rates. however, data are available to assess intermediate outcomes from screening, including the performance characteristics of the screening tests and shifts in disease stage.
## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru
Background. Prostate specific antigen (PSA) is a zymogen of a 33-kilodalton (kD) serine proteinase with extensive similarity to glandular kallikreins. The mechanism responsible for converting the zymogen into active proteinase has not been defined, but active PSA may be irreversibly inactivated in v
The volume of the transition zone was also measured by TRUS in 134 patients.